No deal bucko
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

PointsBet (ASX:PBH) has essentially rejected BlueBet’s Wednesday takeover offer of the company based on the fact the latter needs to raise $160M to pull it off and that benefits were based on ‘assumed synergies.’

In other words: they’ve told BlueBet to get real.

Complicating matters is that the company already faces a takeover offer from another company called MIXI. PointsBet and MIXI are both reportedly undertaking exclusivity arrangements.

While BlueBet’s offer could value PointsBet up to $1.09/sh, there are the aforementioned issues which make MIXI’s offer of $1.06/sh a more enticing deal.

Mainly, MIXI actually has the money.

“The Board determined that the [BlueBet] Proposal could not reasonably be expected to lead to a superior proposal to that announced earlier today from MIXI,” PointsBet wrote on Thursday.

“The [BlueBet] Proposal was unfunded, subject to an explicit financing condition, and would require BlueBet to both raise $100m in debt and undertake a large upfront capital raising.

PointsBet also took issue with BlueBet’s vague wording around ‘synergies’ – no details of what those synergies would actually be or look like were included in Wednesday’s offer.

PBH last traded at $1.12/sh.

Join the discussion: See what HotCopper users are saying about PointsBet and be part of the conversations that move the markets.

pbh by the numbers
More From The Market Online

Listen: HotCopper Wire Podcast #047 – Maybe just send an email next time, Albo

In this week’s HotCopper Wire episode, Isaac McIntyre and Jonathon Davidson break down (poke holes in) Albo’s national address from 7PM Wednesday, talk
The Market Online Video

Introducing Prairie Lithium: Saskatchewan’s permitted lithium project ready to scale

We've spoken to Prairie Lithium founder Zach Maurer about the explorer's overall mission, right after Macquarie's…
The Market Online Video

US growth, injectable iron pipeline: How AFT Pharma is driving toward $300 million by FY27

AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and
The Market Online graphic with ASX-branded charts and the text "HotCopper Highlights" centred in white.

HotCopper Highlights, Week 15: Santos, Karoon, Viva all riding the Iran-fuelled Energy rollercoaster

Hello, hello, and welcome to HotCopper Highlights for Week 15, CY26, I’m Isaac McIntyre.